Gunderson Dettmer represented client ARCH Venture Partners in leading the $270 million Series A financing of Orbital Therapeutics, a company focused on enhancing global health. Orbital Therapeutics is building a first-in-kind platform at the intersection of RNA technology, delivery methods, data science and automation to develop an expansive portfolio of medicines, initially focused in the areas of vaccines, immunomodulation, and protein replacement.

In the announcement of the transaction, ARCH Venture Partners managing partner, and co-founder and board director of Orbital Kristina Burow said, “Few companies can possess the know-how, technology and biologic insights to deliver on the full breadth of opportunity that RNA medicines could provide for patients. Orbital was founded and has been built to be that special company. We are pleased to partner with Orbital’s team of industry leaders and visionaries in drug development to help them achieve a bold mission of bringing forward the next generation of RNA-based medicines.”

The Gunderson Dettmer deal team was led by Kirt Shuldberg and included Riley Millender and Will Fogarty.

Companies
ARCH Ventures Partners
Orbital Therapeutics